Biological Effects and Cellular Uptake of c-myc Antisense Oligonucleotides and Their Cationic Liposome Complexes

References

• Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 1996; 14: 376–387
   PubMed Web of Science ®Google Scholar
• Akhtar S., Juliano R. L. Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol. 1992; 2: 139–144
   PubMedGoogle Scholar
• Bennett C. F., Chiang M.-Y., Chan H., Shomaker J. E., Mirabelli C. K. Cationic lipids enhance cellular uptake and activity of phosphorothioated antisense oligonucleotides. Mol. Pharmacol. 1992; 41: 1023–1033
   PubMed Web of Science ®Google Scholar
• Bennett C. F. Intracellular delivery of oligonucleotides with cationic liposomes. Delivery Strategies for Antisense Oligonucleotide Therapeutics, S. Akhtar. CRC Press, FL 1995; 223–232
   Google Scholar
• Bergan R., Connell Y., Fahmy B., Neckers L. Electroporation enhances c-myc antisense oligonucleotide efficacy. Nucl. Acids Res. 1993; 21: 3563–3573
   PubMedGoogle Scholar
• Bergan R., Hakim F., Schwarts G. N., Kyle E., Cepada R., Szabo J. M., Fowler D., Gress R., Neckers L. Electroporation of Synthetic oligonucleotides: A novel technique for ex vivo bone marrow purging. Blood 1996; 88: 731–741
   PubMed Web of Science ®Google Scholar
• Bradford M. M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976; 72: 248–254
   PubMed Web of Science ®Google Scholar
• Burgess T. L., Fisher E. F., Ross S. L., Bready J. V., Qian Y.-X., Bayewitch L. A., Cohen A. M., Herrera C. J., Hu S. S.-F., Kramer T. B., Lott F. D., Martin F. H., Pierce G. F., Simonet L., Farrell C. L. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. U.S.A. 1995; 92: 4051–4055
   PubMed Web of Science ®Google Scholar
• Crooke S. T. Oligonucleotides as potential therapeutic agents. Trends and Future Perspectives in Peptide and Protein Drug Delivery, V. H.L. Lee, M. Hashida, Y. Mizushima. Harwood Academic Publishers, Chur 1995; 297–320
   Google Scholar
• Crooke S. T., Bennett C. F. Progress in antisense oligonucleotide therapeutics. Annu. Rev. Pharmacol. Toxicol. 1996; 36: 107–129
   PubMed Web of Science ®Google Scholar
• Dean N. M., McKay R., Miraglia L., Geiger T., Muller M., Fabbro D., Bennett C. F. Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents. Biochem. Society Transact. 1996; 24: 623–629
   PubMed Web of Science ®Google Scholar
• Deitch A. D., Law H., White R. D. A stable propidium iodide staining procedure for flow cytometry. J. Histochem. Cytochem. 1982; 30: 967–972
   PubMed Web of Science ®Google Scholar
• Einat M., Resnitzky D., Kimchi A. Close link reduction of c-myc expression by infection and, G0/G1 arrest. Nature 1985; 313: 597–600
   PubMed Web of Science ®Google Scholar
• Galbraith W. M., Hobson W. C., Giclas P. C., Schechter P. J., Agrawal S. Complement activation and hemodynamic changes following intravenous administration of phosphor-othioate oligonucleotides in the monkey. Antisense Res. Develop. 1994; 4: 201–206
   PubMedGoogle Scholar
• Konopka K., Pretzer E., Feigner P. L., Duzgunes N. Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes. Biochim. Biophys. Acta. 1996; 1312: 186–196
   PubMed Web of Science ®Google Scholar
• Litzinger D. C., Brown J. M., Wala I., Kaufman S. A., Van G. Y., Farrell C. L., Collins D. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim. Biophys. Acta. 1996; 1281: 139–149
   PubMed Web of Science ®Google Scholar
• Mahato R. I., Takakura Y., Hashida M. Development of targeted delivery systems for nucleic acid drug. J. Drug Targeting 1997a; 4: 337–357
   PubMed Web of Science ®Google Scholar
• Mahato R. I., Takemura S., Nishikawa M., Takakura Y., Hashida M. Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly (L-lysine). Biochem. Pharmacol. 1997b; 53: 887–895
   PubMed Web of Science ®Google Scholar
• Miyao T., Takakura Y., Akiyama T., Yoneda F., Sezaki H., Hashida M. Stability and pharmacokinetic characteristics of oligonucleotides modified at terminal linkages in mice. Antisense Res. Dev. 1995; 5: 115–121
   PubMedGoogle Scholar
• Mosmann T. J. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983; 65: 55–63
   PubMed Web of Science ®Google Scholar
• Nakai D., Seita T., Terasaki T., Iwasa S., Shoji Y., Mizushima Y., Sugiyama Y. Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15. J. Pharmacol. Exp. Ther. 1996; 278: 1362–1372
   PubMed Web of Science ®Google Scholar
• Nestle F. O., Mitra R. S., Bennett C. F., Chan H., Nickoloff B. J. Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J. Invest. Dermatol. 1994; 103: 569–575
   PubMed Web of Science ®Google Scholar
• Perez J. R., Li Y., Stein C. A., Majumder S., Van Oorschot A., Narayanan R. Sequence-independent induction of Spl transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 5957–5961
   PubMed Web of Science ®Google Scholar
• Sarmiento U. M., Perez J. R., Becker J. M., Narayanan R. In vivo toxicological effects of rel A antisense phosphor-othioates in CD-1 mice. Antisense Res. Develop. 1994; 4: 99–107
   PubMedGoogle Scholar
• Sawai K., Miyao T., Takakura Y., Hashida M. Renal disposition characteristics of oligonucleotides modified at terminal linkages in the perfused rat kidney. Antisense Res. Dev. 1995; 5: 279–287
   PubMedGoogle Scholar
• Sawai K., Mahato R. I., Oka Y., Takakura Y., Hashida M. Disposition of oligonucleotides in isolated perfused rat kidney: involvement of scavenger receptors in their renal uptake. J. Pharmacol. Exp. Ther. 1996; 279: 284–290
   PubMed Web of Science ®Google Scholar
• Shoji Y., Shimada J., Mizushima Y., Iwasawa A., Nakamura Y., Inouye K., Azuma T., Sakurai M., Nishimura T. Cellular uptake and biological effects of antisense oligonucleotide analogs targeted to herpes simplex virus. Antimicrob. Agents Chemother. 1996; 40: 1670–1675
   PubMed Web of Science ®Google Scholar
• Stein C. A., Cheng Y.-C. Antisense oligonucleotides as therapeutic agents-Is the bullet really magical?. Science 1993; 261: 1004–1012
   PubMed Web of Science ®Google Scholar
• Takakura Y., Mahato R. I., Yoshida M., Kanamaru T., Hashida M. Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system. Antisense Nucl. Acid Drug Dev. 1996; 6: 177–183
   PubMedGoogle Scholar
• Tonkinson J. L., Stein C. A. Antisense oligonucleotides as clinical therapeutic agents. Cancer Invest. 1996; 14: 54–65
   PubMed Web of Science ®Google Scholar
• Yaswen P., Stampfer M. R., Ghosh K., Cohen J. S. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res. Dev. 1993; 3: 67–77
   PubMedGoogle Scholar
• Zelphati O., Szoka F. C., Jr. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. U.S.A. 1996; 93: 11493–11498
   PubMed Web of Science ®Google Scholar